Epigenetics

Epigenetics research delves into the molecular mechanisms that control gene expression and cellular traits without altering the underlying DNA sequence. One crucial aspect of this field is the role of small molecules, which act as powerful regulators of epigenetic modifications. These small compounds, typically comprising a few dozen to a few hundred atoms, have emerged as essential tools in understanding and manipulating the epigenome.

  • DNA Methylation Inhibitors: Small molecules like 5-azacytidine and 5-aza-2'-deoxycytidine are DNA methyltransferase inhibitors. They block the addition of methyl groups to DNA, leading to DNA demethylation. This can reactivate silenced genes, potentially offering therapeutic avenues for conditions like cancer.
  • HDAC inhibitors: HDACs remove acetyl groups from histone proteins, contributing to gene repression. Small molecule HDAC inhibitors, such as Vorinostat and Romidepsin, can reverse this process by increasing histone acetylation, allowing genes to be more accessible for transcription. These inhibitors are being explored for cancer therapy and other conditions.
  • Histone Methyltransferase Inhibitors: Small molecules like GSK126 inhibit specific histone methyltransferases, affecting histone methylation patterns. This can alter gene expression, making them promising candidates for cancer and other diseases with epigenetic dysregulation.
  • RNA Modulators: Small molecules can also target non-coding RNAs involved in epigenetic regulation. For instance, small molecules called small interfering RNAs (siRNAs) can be designed to target and degrade specific long non-coding RNAs, influencing gene expression.
  • Epigenetic Reader Domain Inhibitors: These small molecules target proteins that recognize and bind to specific epigenetic marks. Examples include inhibitors of bromodomain-containing proteins (BET inhibitors), which can disrupt gene regulation by interfering with protein-DNA interactions.

Small molecules in epigenetics research not only provide insights into the fundamental biology of gene regulation but also hold immense promise for developing novel therapeutics. Their ability to selectively modulate specific epigenetic marks and pathways has led to ongoing clinical trials and drug development efforts for various diseases, including cancer, neurological disorders, and inflammatory conditions. Understanding and harnessing the power of these small molecules is at the forefront of modern epigenetics research, offering new hope for precision medicine and targeted therapies.


3 key components involved in the regulation of epigenetic modifications

Epigenetics Writer

Epigenetics writers are enzymes responsible for adding chemical marks or modifications to DNA or histone proteins. These marks include DNA methylation (addition of methyl groups to DNA) and histone modifications (such as acetylation, methylation, phosphorylation, etc.).

Epigenetics Reader

Function: Epigenetics readers are proteins that can recognize and bind to specific epigenetic marks on DNA or histones. These reader proteins interpret the epigenetic code and facilitate downstream cellular processes, such as gene activation or repression.

Epigenetics Eraser

Function: Epigenetics erasers are enzymes responsible for removing or reversing epigenetic marks on DNA or histones. This process allows for the dynamic regulation of gene expression and the resetting of epigenetic states during various stages of development and in response to environmental changes.

Shop By

Items 401-450 of 2164

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. PARP-1 inhibitor

    BYK204165 is a cell-permeable isoquinolinedione compound that potently and selectively inhibits poly (ADP-ribose) polymerase 1 (PARP1).
  2. PARP-1/PARP-2 inhibitor

    BYK 49187, PARP-1 and PARP-2 inhibitor (pIC50 values are 8.36 and 7.50 for cell-free recombinant PARP-1 and murine PARP-2 respectively).
  3. PARP inhibitor

    PARP Inhibitor XIDR 2313, PARP Inhibitor XI, is a water soluble pyrimidinone compound that functions as a PARP (Poly(ADP-ribose) polymerase) inhibitor.
  4. PARP1 Inhibitor

    EB 47 is a potent inhibitor of PARP1 with IC50 of 45 nM.
  5. PARP inhibitor

    NU 1025 is a potent poly(ADP-ribose) polymerase (PARP) inhibitor, which potentiates the cytotoxicity of a panel of mechanistically diverse anti-cancer agents in L1210 cells.
  6. Calcineurin-NFAT inhibitor

    INCA-6 is a potent and selective inhibitor of calcineurin-NFAT (Nuclear Factor of Activated T cells) signaling.
  7. PTPMT1 inhibitor

    Alexidine is an alkyl bis(biguanide) antiseptic which has been used in mouthwashes to eliminate plaque forming microorganisms.
  8. PTP inhibitor

    BVT 948 is a non-competitive PTP (protein tyrosine phosphatase) inhibitor.
  9. SHP1/2 PTPase Inhibitor

    NSC 87877 is a potent inhibitor of shp2 and shp1 protein tyrosine phosphatases (SH-PTP2 and SH-PTP1).
  10. HDAC6 inhibitor

    TCS HDAC6 20b, selective inhibitor of histone deacetylase 6 (HDAC6). Inhibits HCT116 growth in combination with taxol. Also inhibits growth of MCF-7 cells stimulated by estrogen.
  11. G9a inhibitor

    UNC0224 is a potent and selective G9a inhibitor with IC50 of 15 nM in in the G9a Thioglo assay.
  12. JAK2 inhibitor

    NSC 33994 is novel inhibitor of JAK2 tyrosine kinase (Janus kinase 2 ). Janus kinase 2 (JAK2) plays a crucial role in the pathomechanism of myeloproliferative disorders and hematological malignancies.
  13. PTP1B Inhibitor

    TCS 401 is a selective inhibitor of protein-tyrosine phosphatase 1B (PTP1B) (Ki values are 0.29, 59, 560, 1100, > 2000, > 2000 and > 2000 μM for PTP1B, CD45 D1D2, PTPβ, PTPε D1, SHP-1, PTPα D1 and LAR D1D2 respectively).
  14. Calcineurin inhibitor

    Cyclosporine is a calcineurin phosphatase pathway inhibitor, used as an immunosuppressant drug to prevent rejection in organ transplantation.
  15. PRMT3 Inhibitor

    SGC 707 is a potent allosteric inhibitor of PRMT3 (IC50 = 50 nM) with >100-fold selectivity over other methyltransferases and other non-epigenetic targets.
  16. HDAC inhibitor

    BRD73954 is a small molecule inhibitor that potently inhibits both HDAC6 and HDAC8 (IC50s = 36 and 120 nM, respectively).
  17. EZH2 Inhibitor

    EPZ011989 is a potent, selective orally bioavailable EZH2 inhibitor with Ki < 3 nM for EZH2 wt and EZH2 Y646; 15-fold selectivity over EZH1 and >3000-fold selectivity over other HMTase.
  18. EZH2 Inhibitor

    GSK-503 is a potent EZH2 inhibitor with potential anticancer activity.
  19. HDAC/ACE inhibitor

    Sinapinic acid (Sinapic acid) is a phenolic compound isolated from Hydnophytum formicarum Jack. Rhizome, acts as an inhibitor of HDAC, with an IC50 of 2.27 mM, and also inhibits ACE-I activity. Sinapinic acid posssess potent anti-tumor activity, induces apoptosis of tumor cells.
  20. KAT5 (Tip60) HAT inhibitor

    NU9056 is an selective KAT5 (Tip60) HAT inhibitor. IC50 values are < 2, 60, 36, and >100 μM for KAT5, p300, pCAF and GCN5, respectively. Inhibits protein acetylation in prostate cancer cell lines and blocks DNA damage response. Decreases proliferation of LNCaP cells; induces apoptosis via caspase activation.
  21. TRIM24/BRPF1 inhibitor

    IACS-9571 is a potent and selective inhibitor of TRIM24 and BRPF1, with IC50 of 8 nM for TRIM24, and Kds of 31 nM and 14 nM for TRIM24 and BRPF1, respectively.
  22. DNMT inhibitor

    6-Methyl-5-azacytidine is a potent DNMT inhibitor.
  23. Aurora Kinase A Inhibitor

    MK-8745 is a novel Aurora-A specific inhibitor. It induces apoptotic cell death in a p53-dependent manner when tested in vitro in cell lines of multiple lineages.
  24. HDAC inhibitor

    N/A
  25. BRPF1 bromodomain inhibitor

    PFI-4 is a potent and selective and cell permeable BRPF1 bromodomain inhibitor (IC50 = 80 nM). Exhibits >100-fold selectivity for BRPF1 over a panel of other bromodomains including BRPF2 (BRD1), BRPF3 and BRD4.
  26. CDK/JAK2/FLT3 inhibitor

    SB1317 is a potent inhibitor of Cyclin dependent kinases (CDKs), FMS-like tyrosine kinase-3 (FLT3) and Janus kinase 2 (JAK2) with IC50 values of 13nM, 56nM and 73nM for CDK2, JAK2 and FLT3, respectively.
  27. HDACs/mTOR Inhibitor 1

    HDACs/mTOR Inhibitor 1 is a dual Histone Deacetylases (HDACs) and mammalian target of Rapamycin (mTOR) target inhibitor for treating hematologic malignancies.
  28. JAK3 inhibitor

    ZM 39923 HCl is an inhibitor of JAK3 (IC50 = 79 nM) that less potently inhibits epidermal growth factor receptor, JAK1, and cyclin-dependent kinase 4 (IC50s = 2.4, 40, and 10 M, respectively)
  29. Aurora kinase A inhibitor

    TC-A-2317 hydrochloride is a potent Aurora kinase A inhibitor (Ki = 1.2 nM compared to 101 nM for inhibition of Aurora kinase B). Selective over 60 other kinases (IC50 values > 1000 nM). Exhibits good cell permeability and antitumor activity.
  30. G9a/GLP inhibitor

    UNC 0638 is a selective inhibitor of G9a and GLP histone lysine methyltransferases.
  31. MGMT inhibitor

    O6-Benzylguanine is an effective substrate and efficient inactivator of DNA alkyltransferase. O6-Benzylguanine is an inhibitor of MGMT.
  32. L3MBTL inhibitor

    UNC669 is a small-molecule antagonist of methyl-lysine (KMe) reader protein with selectivity for L3MBTL1 and L3MBTL3 (IC50 of 4.2μM and 3.1μM respectively)
  33. TNKS1/2 inhibitor

    JW 55 is an inhibitor of the PARP domain of tankyrase 1 and 2 (TNKS1/2).
  34. BRD4 inhibitor

    MS436 is a diazobenzene-based small-molecule inhibitor for the BRD4 bromodomains with a Ki value of 30-50 nM.
  35. PRMT1 inhibitor

    C7280948 is an inhibitor of histone arginine methyltransferase PRMT1 with IC50 values of 12.75 uM.
  36. BET inhibitor

    OTX015 is an orally bioavailable, small molecule inhibitor of BRD2, BRD3, and BRD4 (EC50s = 10-19 nM).
  37. Pim-1 inhibitor

    Hispidulin is a natural flavone with a broad spectrum of biological activities. Hispidulin is a Pim-1 inhibitor with an IC50 of 2.71 μM.
  38. EZH2 inhibitor

    3-deazaneplanocin A, also known as DZNep, is a well-known histone methyltransferase inhibitor, which disrupts polycomb-repressive complex 2 (PRC2), and induces apoptosis, while inhibiting proliferation and metastasis, in cancer cells, including acute myeloid leukemia, breast cancer and glioblastoma.
  39. BET bromodomain inhibitor

    RVX-208 is a potent BET bromodomain inhibitor with IC50 of 0.510 uM for BD2, about 170-fold selectivity over BD1.
  40. JAK3 inhibitor

    Decernotinib is an oral, selective Janus kinase 3 (JAK3) inhibitor being developed by Vertex.
  41. BAZ2A and BAZ2B inhibitor

    GSK2801 is a very potent inhibitor of the BAZ2 family of bromodomain containing proteins
  42. HDAC6 inhibitor

    Nexturastat A is an aryl urea derivative that acts as a potent and highly selective inhibitor of histone deacetylase 6 (HDAC6) (IC50= 5.02 +/- 0.60 nM).
  43. JAK3 inhibitor

    WHI-P 154 is a JAK3 inhibitor with IC50 = 1.8uM. WHI-P 154 also Inhibits STAT1 activation, iNOS expression and NO production in macrophages in vitro.
  44. Aurora A/B inhibitor

    SCH-1473759 is a novel sub-nanomolar Aurora A/B inhibitor with IC50 of 4 nM and 13 nM, respectively.
  45. DNMT inhibitor

    SGI 1027 is a DNMT inhibitor with IC50 of 6, 8, 7.5 uM for DNMT1, DNMT3A, and DNMT3B, respectively.
  46. JAK2 inhibitor

    Z3 is a novel specific inhibitor of Jak2 tyrosine kinase.
  47. GSK 525768A is the enantiomer compound of GSK 525762A, which is a potent small molecule inhibitor that disrupt the function of the BET family of bromodomains (Brd2, Brd3, and Brd4); GSK 525768A has NO activity towards BET.
  48. Dual Syk and JAK inhibitor

    PRT062070 is a novel, oral, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor. Cerdulatinib preferentially inhibited JAK1 and JAK3 dependent cytokine mediated signaling and functional responses in various cell types.
  49. BET bromodomain inhibitor

    The bromodomain and extra terminal domain (BET) family of proteins, including BRD2, BRD3, and BRD4, play a key role in many cellular processes, including inflammatory gene expression, mitosis, and viral/host interaction by controlling the assembly of histone acetylation-dependent chromatin complexes.
  50. HDAC6 inhibitor

    HPOB is a potent inhibitor of histone deacetylase 6 (HDAC6; IC50 = 56 nM).

Items 401-450 of 2164

Page
per page
Set Descending Direction